4
Changes in Ownership
Ultragenyx Pharmaceutical Inc. Filed Acc 0001209191-18-036501
CFO & Executive Vice President sold 6,700 shares at $80.07 ($536,456)
- CFO & Executive Vice President acquired 3,350 shares (option exercise)
From the SEC's structured data for this filing
Trades in this filing
Sharp Shalini · CFO & Executive Vice President
Table I: Non-derivative
2 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2018-06-07 | Exercise or conversion : show line 1 in the form | +3,350 | $0.82 | $2,730 | 60,178 | D |
| 2018-06-07 | Sale : show line 2 in the form | −6,700 | $80.07 | $536,456 | 53,478 | D |
| Open-market sales · 6,700 sh · avg $80.07 · $536,456 | ||||||
Table II: Derivative
1 line| Date | Transaction | Shares | Exercise | Expires | Underlying | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| 2018-06-07 | Exercise or conversion : show line 3 in the form Stock Option (Right to Buy) | −3,350 | $0.82 | 2022-08-01 | 3,350 | 22,313 | D |
Loading xslF345X03/doc4.xml…